| 词条 | Pidilizumab |
| 释义 |
| type = mab | image = | alt = | mab_type = mab | source = zu/o | target = DLL1 | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|correct|CAS}} | CAS_number = 1036730-42-3 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = B932PAQ1BQ | KEGG = D10390 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank = | ChemSpiderID = none | C=6424 | H=9920 | N=1704 | O=2002 | S=48 | molecular_weight = 147.43 kg/mol }} Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases.[1][2] Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule.[3] Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells. Clinical trialsIt had encouraging results by 2011 from phase II clinical trials for diffuse large B-cell lymphoma.[4] A phase II open-label study in combination for relapsed follicular lymphoma found good results compared to usual response rates. A phase I/II open label study in pediatric patients with a rare form of brain cancer, diffuse intrinsic pontine glioma, found improvement in overall survival compared to expected outcome.{{cn|date=July 2017}} An add-on trial for multiple myeloma is ongoing.[5] References1. ^{{cite journal |title=Safety and Activity of PD1 Blockade by Pidilizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: a Single Group, Open-label, Phase 2 Trial |year=2014 |author=Westin|doi=10.1016/S1470-2045(13)70551-5|display-authors=etal |pmid=24332512 |pmc=3922714 |volume=15 |journal=Lancet Oncol. |pages=69–77}} {{monoclonals for immune system}}{{monoclonal-antibody-stub}}2. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Pidilizumab, American Medical Association- needs login. 3. ^http://www.fiercebiotech.com/story/anti-pd-1-well-no-says-medivation-partial-hold-forces-halt-pivotal-cancer-s/2016-01-26 4. ^Teva Invests $19M More in CureTech After Positive Phase II DLBCL Data. Sept 2011 5. ^{{Cite web|title = Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma - Full Text View - ClinicalTrials.gov|url = https://clinicaltrials.gov/ct2/show/NCT02077959|website = clinicaltrials.gov|accessdate = 2015-08-22}} 2 : Monoclonal antibodies|Experimental drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。